belantamab mafodotin
gsk
['belantamab']
belantamab-vrd in transplant ineligible new dx mm. single arm study of 93 pts, grade 3 ocular toxicity in 53% patients. 7 patients with fatal adverse events- none of which apparently attributed to therapy. this drug doesn t belong here. #asco23 
Cancer doctor at @huntsmancancer with interest in myeloma, supportive care, end of life, cost-effective/evidence-based care and med-ed. No COI. Views own.